January 11, 2017

January 10, 2017

Subscribe to Latest Legal News and Analysis

January 09, 2017

Subscribe to Latest Legal News and Analysis

Effective Dec 1, Pharmacies, Prescribers, and Wholesalers Must Report Gabapentin to Ohio Automated Rx Reporting System

Beginning December 1, 2016, the State of Ohio Board of Pharmacy requires pharmacies, prescribers, and wholesalers to report the dispensing, personal furnishing, and wholesale sale of all products containing gabapentin (brand names: Neurontin, Gralise, Horizant) to the Ohio Automated Rx Reporting System (OARRS). Gabapentin has not been reclassified as a controlled substance, but it is being added to the Board’s list of drugs reportable to OARRS following increased reports of misuse, abuse, and concomitant abuse of gabapentin nationwide.1

No new requirement to review an OARRS report prior to dispensing gabapentin

Unlike the rules requiring pharmacists and prescribers to request and review an OARRS report prior to dispensing, prescribing, or personally furnishing controlled substances, there is no requirement to request and review an OARRS report prior to dispensing, prescribing, or personally furnishing gabapentin. Pharmacists and prescribers are expected to use professional judgment to determine the need to request an OARRS report prior to dispensing, prescribing or personally furnishing gabapentin.

Changes to prior exemptions to reporting

Pharmacies or prescribers that were previously exempt from OARRS reporting requirements because they did not dispense or personally furnish controlled substances do not need to reapply for a reporting exemption if they do not dispense or personally furnish gabapentin. However, pharmacies and prescribers that were previously exempt from OARRS reporting requirements, but do dispense or personally furnish gabapentin, must begin reporting such dispensing or personal furnishing to OARRS effective December 1, 2016.

More information on reporting to OARRS can be found in the Ohio PMP Handbook, available under the Pharmacies & Prescribers section on the OARRS website.


DEA Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective, September, 2015.

© 2017 Dinsmore & Shohl LLP. All rights reserved.

TRENDING LEGAL ANALYSIS


About this Author

Eric J. Plinke, Dinsmore Law, Health Care Lawyer, Corporate Attorney
Partner

Eric Plinke is a Partner in the Corporate Department and Health Law Practice Group, and he routinely advises corporate and individual clients regarding a wide-range of health care industry legal issues. He has counseled clients in practice formation and acquisition, hospital and joint venture transactions, hospital and medical practice affiliations, contract review and preparation, compliance programs, HIPAA regulations, scope of practice issues, telemedicine and Stark law and Anti-kickback statutes, as well as significant experience counseling in ambulatory surgery centers and other joint...

614-227-4213
Sarah C. Persinger PharmD RPh, Dinsmore, managed care lawyer, pharmacy benefits management attorney
Associate

Sarah is a member of our Health Care Practice Group. She holds a Doctor of Pharmacy degree and is a registered pharmacist with extensive pharmacy practice experience and a working knowledge of regulatory affairs. She has managed health system pharmacy compliance with Ohio State Board of Pharmacy, DEA, and CMS regulations, the federal 340B Drug Discount Program, USP 797 and FDA Sterile Compounding requirements, and Joint Commission and HFAP Accreditation standards. 

Sarah has a strong working knowledge of specialty pharmacy, managed care and pharmacy benefits management, HIPAA and healthcare information security, and trade association industry relations, as well as work experience in the retail, hospital, and long term care pharmacy practice settings. 

(614) 628-6979
Daniel S. Zinsmaster, Dinsmore, Health Care Lawyer,
Associate

With extensive experience in the health care arena, Daniel provides trusted counsel to clients on a variety of matters, including administrative and disciplinary proceedings, as well as regulatory investigations and compliance. Prior to joining Dinsmore, Daniel practiced for nearly seven years with the State Medical Board of Ohio, where he advised Board members and agency personnel on issues related to the Medical Practices Act of Ohio, Chapter 119 Administrative Procedures, and federal rules and regulations implicating the area of health care. His experience with the...

(614) 628-6949